Search

News & Events

A bold respiratory research project will investigate whether wearable devices could drastically change clinical care for children living with chronic diseases such as cystic fibrosis. 

The Kids Research Institute Australia, Perth Children’s Hospital Foundation and Perth Children’s Hospital have formed a strategic partnership to support the establishment and operation of the Wal-yan Respiratory Research Centre.

Find out how you can get involved with our work at Phage WA.

Here are some of the most common questions about phage, phage therapy and antimicrobial resistance (AMR).

A public health campaign to raise awareness about the dangers of chronic wet cough in Aboriginal children is helping to improve detection, diagnosis and management of the condition.

Learn more about all of the Clinical Trials, Platforms & Cohorts at the Wal-yan respiratory centre.

Cystic fibrosis (CF) is the most common life‐shortening genetic disease affecting children.

On average, a person can expect to take more than 700 million breaths in their lifetime.

Respiratory disease is a global issue and international networks are critical to informing best-practice approaches to the clinical care and management of childhood respiratory health.

Research

Mutation-agnostic treatments such as airway gene therapy have the potential to treat any individual with cystic fibrosis (CF), irrespective of their CF transmembrane conductance regulator (CFTR) gene variants. The aim of this study was to employ two CF rat models, Phe508del and CFTR knockout to assess the comparative effectiveness of CFTR modulators and lentiviral vector-mediated gene therapy.